Hypertension in patients with diabetes mellitus

Czech version

Authors: M. Souček
Authors‘ workplace: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MU Dr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2010; 56(9): 995-999
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Overview

Hypertension in patients with type 2 diabetes mellitus (DM) is one of the most frequent, most serious but treatable risk factors. The results of randomised studies clearly show the benefits of improved blood pressure control in type 2 DM patients but achievement of target blood pressure values in clinical practice remains a major problem. Type 2 DM, and primarily increased systolic blood pressure, significantly worsen patient prognosis with respect to microvascular as well as macrovascular complications. Recommendations by the European Society of Hypertension and the European Society of Cardiology emphasise the need for good diagnostics and effective management, predominantly using combination therapy. In 2009 a revision of recommendations for diagnostics and treatment of hypertension was issued that defines initiation of hypertension therapy in type 2 DM patients and target values and presents results of the most recent studies.

Key words:
hypertension – diabetes mellitus – hypertension control in diabetes – cardiovascular risk

Sources

1. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care 2004; 27: 2568– 2569.

2. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: astatement for health care professional from the American Heart Association. Circulation 1999; 100: 1134– 1346.

3. Wilson PW, D’Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837– 1847.

4. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821– 827.

5. Sowers JR, Farrow SL. Treatment of elderly hypertensive patients with diabetes, renal disease and coronary heart disease. Am J Geriatr Cardiol 1996; 5: 57– 70.

6. Cífková R. Léčba hypertenze u pacientů s diabetem. Farmakoterapie 2008; 3: 303– 308.

7. Mancia G, De Backer C, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105– 1187.

8. Tarnow L, Rossing P, Gall MA et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC‑ V. Diabetes Care 1994; 17: 1247– 1251.

9. Grossmann E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med 1996; 125: 304– 310.

10. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non‑insulin‑dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157: 1413– 1418.

11. Borch‑ Johnson K, Nissen R, Nerup J. Blood pressure after 40 years of insulin dependent diabetes. Neohron 1985; 4: 11– 12.

12. Mancia G, Laurent S, Agabiti‑ Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121– 2153.

13. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lower? A critical reappraisal. J Hypertens 2009; 27: 923– 934.

14. Hannson L, Zanchetti A, Carruthers SG et al. Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized Trial. Lancet 1998; 351: 1755– 1762.

15. UK Prospektive Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703– 713.

16. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829– 840.

17. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‑risk patients. N Engl J Med 2008; 359: 2417– 2428.

18. Dahlöf B, Sever P, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertesive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑ Scandinavian Cardiac Aoutcomes Trial‑ Blood Pressure Lowering Arm (ASCOT‑ BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895– 906.

19. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‑blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782– 788.

20. Cushman WC, Evans GW, Byington RP et al. ACCORD Study Group. Effects of intensive blood‑ pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575– 1585.

21. Vítovec J, Špinar J. Použití betablokátorů u nemocných s diabetes mellitus. Intern Med 2008; 10: 126– 128.

22. Goff DC Jr, Gerstein HC, Ginsberg HN et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i–20i.

23. Gaede P, Lund‑ Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580– 591.

24. Holmann RR, Paul SK, Bethel MA et al. 10 years follow‑up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577– 1589.

25. Zanchetti A, Hansson L, Dahlöf B et al. Benefit and harm of low‑dose aspirin in well‑treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20: 2301– 2307.